Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"I expect results from NBS' Phase 2 PreSERVE-AMI trial in Q4/14; that will be proof of concept for this approach." (9/10/14) NeoStem Inc. - The Life Sciences Report Interview with Vernon Bernardino Moreá>
Mark Kessel co-founded Symphony Capital LLC, a private equity firm investing in the clinical development programs of biopharmaceutical companies, in 2002. He is widely recognized as the leader in structuring product development investments for the biopharmaceutical industry. Kessel was formerly the managing partner of Shearman & Sterling, with day-to-day operating responsibility for one of the largest international law firms. He received a bachelor's degree with honors in economics from the City College of New York, and a juris doctor magna cum laude from Syracuse University College of Law. Kessel is currently of counsel to Shearman & Sterling, and a director of Dynavax Technologies Corp., the Foundation for Innovative New Diagnostics and Fondation SantÚ. He also served as a director of the Biotechnology Industry Organization, the Global Alliance for TB Drug Development, OXiGENE Corp., Antigenics Inc., Heller Financial Inc. and Harrods (UK) Limited and as a trustee of the Museum of the City of New York. Kessel has written on financing for the biotech industry for Nature Reviews Drug Discovery, Nature Biotechnology, The Scientist and other publications, and on issues related to governance and audit committees for such publications as The Wall Street Journal, Financial Times, The Deal and Euromoney.
Solving the R&D Investment Dilemma with Project Funding: Mark Kessel (3/21/13) Big pharma knows how to market products. But has it lost a step on the drug development side? Is there a better way to incentivize drug development and make money at it? Mark Kessel, co-founder and partner at private equity firm Symphony Capital LLC, has developed an investment technique that funds promising biotech companies without exposure to all the losses built into a startup model. In this interview with The Life Sciences Report, Kessel talks about his method and how it has worked with specific biotech companies.
"The combination of DMPI's VAL-083 and radiation therapy showed an immediate survival benefit in glioblastoma multiforme." (10/30/14) DelMar Pharmaceuticals Inc. - The Life Sciences Report Interview with Brandon Primack Moreá>